Hepatitis transmission by blood products.
The main causes of hepatitis transmission by blood products are hepatitis B and non A non B hepatitis (NANB). A reduction in hepatitis transmission has been achieved by screening blood donors for hepatitis B surface antigen, but it is not known what the effectiveness of screening donors for raised plasma alanine aminotransferase levels or hepatitis B core antibody will be. Attempts to reduce NANB hepatitis transmission have mainly focussed on heat treatment of factor VIII and IX concentrations, and preliminary data suggests that under certain heating conditions inactivation of the NANBvims occurs. Although albuminoid preparations are known not to transmit hepatitis, three immunoglobulin preparations for intravenous administration (IV IgG) have transmitted hepatitis, suggesting that the inclusion of a terminal virucidal step is essential.
D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents; D001782:Blood Donors; D001798:Blood Proteins / Q000009:adverse effects*; D006509:Hepatitis B / Q000635:transmission*; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D003699:Hepatitis D / Q000635:transmission*; D006801:Humans; D007136:Immunoglobulins / Q000009:adverse effects; D065227:Transfusion Reaction
D000998:Antiviral Agents; D001798:Blood Proteins; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D007136:Immunoglobulins; D000410:Alanine Transaminase